Irenka

Quick links to important sections

Irenka

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Irenka

Quick Facts

Property Description
Active ingredient Duloxetine Hydrochloride
Form Delayed-release capsule
Pharmacological class Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
General Purpose Modulating mood and physical discomfort
Origin Synthetic compound

What Type of Medicine is Irenka and How is it Classified?

Irenka is a prescription-only pharmaceutical preparation containing the active ingredient Duloxetine Hydrochloride. It is formally classified as an Antidepressant Agent, specifically belonging to the group of Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs). This classification is vital as it signifies a dual inhibitor action, providing a targeted approach to managing conditions where both emotional state and persistent physical signals are involved.

Composition, Origin, and Form: Understanding Duloxetine’s Structure

The active component, Duloxetine Hydrochloride, is a synthetic compound administered via oral administration. The drug is formulated as a delayed-release capsule that contains specialized enteric-coated mini tablets. This unique physical form is essential because Duloxetine is highly acid-labile and would otherwise be destroyed by stomach acid, necessitating the protective coating for effective absorption. The capsule design ensures that the drug is delivered intact to the small intestine, guaranteeing the active ingredient can properly reach the central nervous system.

General Purpose: How Irenka Impacts the Nervous System

The overall purpose of Irenka is to help stabilize emotional state and influence the body’s processing of persistent discomfort through its dual-acting mechanism. This action is achieved by increasing the concentration of the neurotransmitters Serotonin and Norepinephrine by inhibiting their neuronal reuptake. By enhancing communication in the neural circuits responsible for maintaining emotional balance and those descending pathways that modulate the intensity of physical signals, the medication provides support.

What side effects are possible with Irenka?

Possible Side Effects and Safety Information

The safety profile of Irenka (Duloxetine Hydrochloride) is formally categorized by regulatory authorities based on the frequency and nature of documented adverse reactions. These classifications help define the established risk characteristics of the medicine, distinguishing between high-frequency expected effects and rare, serious events.

Official Adverse Reaction Classification

Adverse reactions are organized by System-Organ Class (SOC) and assigned regulatory frequency tiers, such as Very Common (ge 1/10) and Common (ge 1/100 to < 1/10). The most frequently reported reactions, classified as Very Common, are nausea, dry mouth, and headache. Other reactions classified as Common often involve the gastrointestinal and nervous systems, including dizziness, somnolence (drowsiness), fatigue, constipation, diarrhea, and increased sweating (hyperhidrosis).

Serious Safety Considerations

The official labeling highlights several serious safety considerations. These include warnings regarding Hepatotoxicity (liver damage, including reports of hepatic failure) and the potential for a life-threatening condition known as Serotonin Syndrome, particularly when the medicine is used concomitantly with other serotonergic agents. Furthermore, regulatory documents contain a mandated statement on the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults receiving this class of medication.

Population-Specific Constraints and Safety Patterns

The medicine is not recommended for use in patients with severe renal impairment or hepatic impairment/chronic liver disease. Safety-related restrictions also include a contraindication against use with Monoamine Oxidase Inhibitors (MAOIs) and in patients with uncontrolled hypertension. Certain effects, such as orthostatic hypotension (a drop in blood pressure upon standing), are reported to occur more frequently at the initiation of treatment. Discontinuation of the medicine is associated with a specific cluster of official withdrawal symptoms.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Irenka (Duloxetine) requires immediate action for any suspected overdose.

Category Official Regulatory Statements
Documented Overdose Presentations Overdose symptoms may include somnolence, agitation, tremor, vomiting, diarrhea, hyperhidrosis (sweating), and pyrexia (fever).
Physiological Systems Affected Central Nervous System (CNS) effects such as seizures and coma are documented, along with Cardiovascular effects like tachycardia (fast heart rate), hypertension, and hypotension.
Severity Classification Severe potential outcomes include Serotonin Syndrome and Neuroleptic Malignant Syndrome (NMS)-like reactions. Fatal outcomes have been reported in overdoses involving the drug with multiple other drugs or alcohol.
Emergency Management Management must be symptomatic and supportive. This includes establishing and maintaining an airway, ensuring adequate oxygenation, and consideration of activated charcoal and gastric lavage.
Antidote and Monitoring The regulatory information states that no specific antidote is known. Continuous cardiac monitoring (ECG) and vital sign observation are required.

When Immediate Medical Help Is Required

The official guidance is to seek immediate medical attention for any suspected overdose and to contact a Poison Control Center for additional management guidance. The drug must be discontinued immediately if Serotonin Syndrome or NMS-like reactions are suspected.

Therapeutic Uses of Irenka

What Irenka treats: main uses and benefits

Irenka (duloxetine) is a medication classified as a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of specific chemical messengers in the brain and nervous system that are responsible for regulating mood and processing pain signals.

Primary Uses

Irenka is used in the management of several distinct conditions involving the central nervous system and chronic pain pathways:

  • Major Depressive Disorder: It is used to help relieve the symptoms of clinical depression, including persistent feelings of sadness and loss of interest.
  • Generalized Anxiety Disorder: It helps manage the physical and mental symptoms of chronic, excessive worry and tension.
  • Diabetic Peripheral Neuropathic Pain: It is used to manage the burning, stabbing, or shooting pain caused by nerve damage in the legs and feet of individuals with diabetes.
  • Fibromyalgia: It is utilized to reduce the widespread muscle pain, stiffness, and fatigue associated with this chronic condition.
  • Chronic Musculoskeletal Pain: It is used for the management of long-term pain in the lower back or pain due to osteoarthritis.

Therapeutic Benefits

The primary benefit of Irenka is its dual action on both emotional and physical symptoms. In conditions like depression and anxiety, the medication helps stabilize mood and reduce psychological distress. In chronic pain conditions, it acts by modulating the way the brain perceives pain signals, providing relief even when there is no acute injury present.

By addressing both the psychological and physical aspects of these conditions, the medication aims to improve a patient's overall daily functioning and quality of life.

Eligibility and Restrictions for Use

Eligibility Scope

Classification Restricted Population/Condition Regulatory Source Basis
Contraindicated Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI treatment. FDA / EMA
Contraindicated Patients with uncontrolled narrow-angle glaucoma. FDA
Contraindicated Severe renal impairment (Creatinine Clearance <30 mL/min). EMA / FDA
Contraindicated Hepatic impairment, including chronic liver disease or cirrhosis. EMA / FDA
Contraindicated Initiation of treatment in patients with uncontrolled hypertension. EMA
Not Established Pediatric patients for Major Depressive Disorder (MDD), Diabetic Peripheral Neuropathic Pain, and Chronic Musculoskeletal Pain. FDA / EMA

Age-Related Eligibility: Use is established for adults (18 years and older) for all approved uses. For Generalized Anxiety Disorder (GAD), use is approved for pediatric patients 7 years of age and older. For Fibromyalgia (FM), use is approved for pediatric patients 13 years of age and older. No dosage adjustment is recommended for older adults based solely on age, but caution is advised.

Conditional Use: Irenka should be used with caution in patients with controlled narrow-angle glaucoma, a history of seizure disorder, or a history of mania/bipolar disorder.

Reproductive Status: Regulatory documents state that use during pregnancy and lactation is permitted only if the potential benefit justifies the potential risk to the fetus or child.

What should I know about interactions with other medicines?

Irenka, which contains duloxetine, has several officially documented interactions that may require caution or avoidance.

Contraindicated and Restricted Combinations

Monoamine Oxidase Inhibitors (MAOIs): Use with MAOIs, including psychiatric MAOIs, linezolid, or intravenous methylene blue, is contraindicated. This combination carries a significant risk of Serotonin Syndrome. A washout period of at least 14 days is required after stopping an MAOI before starting Irenka, and at least 5 days must pass after stopping Irenka before starting an MAOI.

CYP1A2 Inhibitors: Co-administration with potent CYP1A2 inhibitors, such as fluvoxamine, ciprofloxacin, or enoxacin, is avoided because these agents substantially increase Irenka's concentration in the body.

Increased Risks from Concomitant Use

Serotonergic Agents: Caution is necessary when Irenka is used with other serotonergic agents (e.g., SSRIs, SNRIs, Triptans, Tramadol, Thioridazine, or St. John's Wort) due to the heightened risk of Serotonin Syndrome.

Drugs that Interfere with Hemostasis: Irenka may increase the risk of bleeding events. Caution is advised with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or warfarin and other anticoagulants.

CYP2D6 Substrates/Inhibitors: Irenka is a moderate inhibitor of the enzyme CYP2D6. Co-administration may increase the exposure of other medicines metabolized by CYP2D6, particularly those with a narrow therapeutic index, such as certain antiarrhythmics (e.g., propafenone, flecainide).

Alcohol: Use of Irenka with heavy alcohol consumption may be associated with an increased risk of severe liver injury.

Mechanism of Action

Irenka (duloxetine) functions primarily as a selective serotonin and norepinephrine reuptake inhibitor (SNRI) within the central nervous system (CNS).

Its main biological targets are the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). Irenka is an inhibitor of both SERT and NET, blocking the neuronal reuptake of the neurotransmitters serotonin (5-HT) and norepinephrine (NE) from the synaptic cleft into the presynaptic neuron. This blockade results in an elevated concentration and prolonged presence of 5-HT and NE in the synapse, leading to enhanced neurotransmission.

In specific CNS regions, such as the prefrontal cortex, the inhibition of NET also indirectly increases the extracellular concentration of dopamine (DA), as DA reuptake in this area is largely mediated by NET. This modification of signaling constitutes the intracellular pathway.

Downstream, the sustained increase in 5-HT and NE in the synapse modulates various system-level physiological consequences. For instance, in the dorsal horn of the spinal cord, enhanced noradrenergic and serotonergic activity strengthens the descending inhibitory pain pathways. This increase in inhibitory signaling at the spinal level suppresses the transmission of nociceptive input to the brain.

Dosage and Administration Information

How to Use Irenka (Duloxetine) — Administration Guidelines

Irenka is a prescription medication provided as a delayed-release capsule that must be administered orally (by mouth). The medication can be taken with or without food.

Administration Instructions and Restrictions

Instruction Category Procedural Rule
Form The delayed-release capsule must be swallowed whole.
Manipulation The capsule must not be crushed, chewed, or opened to sprinkle the contents, as this may interfere with the intended delayed release.
Timing Administered once daily or twice daily, as prescribed.

Dosing Rules (Select Populations)

The specific daily dosage and titration schedule depend on the condition being addressed and the patient's age. Dosage must be determined by a healthcare provider.

Population / Indication Typical Initial Dosing Regimen
Adults (Initial) Often begins with 30 mg once daily for up to one week before increasing to the target daily dose (e.g., 60 mg/day).
Pediatric GAD (Age 7–17) Initial dose of 30 mg once daily for 2 weeks, then increasing to 60 mg once daily.
Geriatric GAD A lower starting dose (30 mg once daily for 2 weeks) is recommended before increasing to the target dose.

Missed Dose and Discontinuation

If a dose is missed, it should be taken as soon as the patient remembers, unless it is almost time for the next scheduled dose. In that case, the missed dose must be skipped, and the patient should resume the regular schedule; do not take two doses to make up for a missed dose. When discontinuing Irenka, a gradual dose reduction is recommended to minimize the risk of withdrawal symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Irenka


Evidence for Use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

Irenka was studied in adults with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) primarily through short-term and maintenance Randomized Controlled Trials (RCTs). Researchers examined outcomes related to systemic or functional imbalance by monitoring changes in standardized mood and anxiety severity scales. Findings describe patterns observed in the studies, where research explored whether symptom scores measured in the study population differed from those measured in the comparison (placebo) group. Research has also explored how symptoms evolved after an initial measured response, with findings describing patterns related to the measurements taken in the observed populations for up to six months.

Long-term outcomes, particularly for continuous symptom measurement, are not well characterized beyond the established recurrence prevention trials. Comparative evidence against all other available treatment options may be limited in certain contexts.


Evidence for Use in Chronic Pain Conditions: DPNP and Fibromyalgia

The research for conditions involving persistent physical discomfort, such as Diabetic Peripheral Neuropathic Pain (DPNP) and Fibromyalgia (FM), mainly involves short-term to intermediate-term controlled trials. Studies explored symptom intensity and variability by measuring changes in pain severity scores. Research highlights changes measured during the study period, reporting that symptom patterns and functional outcomes were observed in the study populations.

Follow-up durations were limited in the initial trials, and information for long-term outcomes is derived primarily from open-label (uncontrolled) data. For Fibromyalgia, some scientific discussions have noted that the reported measured changes were modest, and the generalizability of the findings to certain patient subgroups is limited.


Limitations and Research Uncertainty

Evidence quality varies across the studies, and key limitations have been noted in scientific literature. Follow-up durations were limited in many initial efficacy trials. While research describes findings related to specific study conditions, comparative evidence against all other available treatment options for each indication is often lacking. Scientific reviews have described variability between the findings reported in some publications and the full data assessed by regulatory agencies.

Key Studies & References

  1. Duloxetine for stress urinary incontinence in women: a review of the evidence.
  2. NICE Guideline NG137: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain

Frequently Asked Questions (FAQ)

Common questions about Irenka (FAQ)


Q: What is the main reason doctors prescribe Irenka?

According to official regulatory documents, Irenka is approved for use in specific health conditions. These approved uses include Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain (DPNP), and Fibromyalgia (FM).

Q: Can Irenka be taken with common over-the-counter pain relievers?

Official product information indicates that caution is required when Irenka is used concomitantly with certain over-the-counter pain relievers, such as aspirin and non-steroidal anti-inflammatory drugs (NSAIDs). This is due to a documented increased risk of bleeding events when these medicines are combined.

Q: What are the most common safety warnings listed for Irenka?

The official prescribing information contains several important warnings. These include a mandated statement about the increased risk of suicidal thoughts and behaviors, especially in children, adolescents, and young adults. Other serious considerations involve the potential for liver injury (hepatotoxicity) and the risk of Serotonin Syndrome, a serious condition related to high serotonin levels.

Q: Are there any dietary restrictions mentioned in the information for Irenka?

Regulatory documents highlight a safety concern regarding alcohol consumption. Using Irenka while consuming substantial amounts of alcohol may be associated with an increased risk of severe liver injury. The medicine can otherwise be taken with or without food.

Q: Does Irenka affect sleep patterns or cause insomnia?

Regulatory documents indicate that somnolence, which is a feeling of drowsiness or excessive sleepiness, is a commonly reported side effect. Insomnia, or difficulty sleeping, has also been noted as one of the symptoms that may occur when the medicine is gradually stopped.

Q: Can Irenka be taken with supplements like vitamins or herbal products?

The official information indicates that caution is necessary when Irenka is used alongside other medicines or supplements that affect serotonin levels. This group includes certain herbal products, such as St. John’s Wort, because the combination is associated with an increased risk of a serious condition called Serotonin Syndrome.

Q: Are there different dosage strengths of Irenka available?

Yes, Irenka is available as delayed-release capsules in different dosage strengths. Official prescribing information lists strengths such as 20 mg, 30 mg, and 60 mg, which are used to treat the approved conditions.

Q: Does Irenka commonly affect blood pressure or heart rate?

Official guidance indicates that blood pressure is monitored prior to treatment initiation and periodically thereafter. A drop in blood pressure when standing up, known as orthostatic hypotension, has been reported. The medicine is not recommended for use in patients with pre-existing uncontrolled high blood pressure.

Q: Are there any warnings about driving or operating machinery while taking Irenka?

Regulatory documents advise exercising caution regarding activities that require mental alertness. Since side effects like dizziness and somnolence (drowsiness) are reported, the official guidance indicates that performing tasks requiring psychomotor coordination, such as driving a car or operating hazardous machinery, may be impaired.

Q: Do Irenka's official documents mention specific heart-related risks?

Official information states that Irenka is contraindicated in patients who have uncontrolled hypertension (high blood pressure). Furthermore, monitoring of blood pressure is described as recommended periodically throughout the treatment period.

Q: Is Irenka considered a new type of drug?

The active ingredient in Irenka, duloxetine, was first approved by the U.S. Food and Drug Administration (FDA) in August 2004.

Q: How long does it typically take to notice the effects of Irenka?

Studies and official information indicate that significant changes in symptoms of depression may start to be measured within the first one to two weeks of beginning treatment. However, the maximum therapeutic benefit may take longer, often requiring four to six weeks.

Q: How is Irenka described as being different from [Similar Drug X]?

Irenka belongs to a class of medicines known as Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs). This means its mechanism involves acting on two neurotransmitters, serotonin and norepinephrine. This dual action is described as the main difference between Irenka and medicines like SSRIs, which primarily affect only serotonin.

Q: Does Irenka commonly cause weight gain or changes in appetite?

Decreased appetite is officially listed as a common side effect for both adults and children. In short-term studies, patients often experienced a small average weight loss. However, some longer-term adult studies have reported modest weight gain in some cases.

Q: Is Irenka addictive or habit-forming?

Official sources state that Irenka is not classified as a controlled substance and is not considered addictive. However, the official guidance on discontinuation recommends a gradual dosage reduction to minimize the occurrence of discontinuation (withdrawal) symptoms.

Q: What inactive ingredients are in Irenka besides the main medicine?

The delayed-release capsule contains inactive ingredients that help form the medicine and ensure its proper delivery in the body. These ingredients include gelatin, sucrose, hypromellose, talc, titanium dioxide, and triethyl citrate, in addition to colorings that may be present.

Q: What are the signs of a serious side effect from Irenka that require immediate attention?

Signs that may indicate a serious reaction include symptoms of Serotonin Syndrome, such as agitation, confusion, rapid heart rate, fever, and muscle stiffness. Other serious signs, such as yellowing of the skin or eyes (jaundice) or severe abdominal pain, may be associated with liver problems.

Q: How long has Irenka been available on the market?

The active ingredient in Irenka, duloxetine, was first approved and introduced to the market in the United States in August 2004.

Q: Is Irenka available as a generic medicine yet?

Yes, the generic version of Irenka, which contains the active ingredient duloxetine, is available. The first generic versions were approved and launched in the United States starting in December 2013.

Q: Do official documents mention Irenka's potential effect on fertility?

Official guidance and clinical literature do not provide clear evidence that Irenka reduces fertility in either men or women. However, specific documentation for the medicine covers use during pregnancy and lactation.

Q: What type of patient monitoring (like blood tests) is described in the official guidance for people taking Irenka?

Regulatory guidance indicates that blood pressure is monitored prior to the initiation of Irenka and periodically during the course of treatment. Furthermore, due to the potential for liver injury, testing may be required if signs of liver dysfunction are noted.

Q: Does Irenka interact with birth control pills?

Official drug interaction information suggests that Irenka may slightly increase the blood levels of one of the active components in some combined birth control pills, known as Ethinyl Estradiol. Patients using oral contraceptives may require monitoring for increased side effects of Irenka.

How should Irenka be stored and disposed of?

Irenka (duloxetine delayed-release capsules) must be stored at Controlled Room Temperature, defined as mathbf20^circmathbfC to mathbf25^circmathbfC (68 F to 77 F). The official label permits temporary temperature excursions between 15 C to 30 C (59 F to 86 F). Storage conditions prohibit freezing and require the medicine to be kept in its original, tightly closed container, protected from excessive heat, moisture, and light. The capsule must be swallowed whole to maintain its delayed-release integrity. All medication must be kept out of the sight and reach of children.

For disposal of unused or expired medicine, regulatory guidance recommends removal from the original container, mixing it with an undesirable substance like used coffee grounds or kitty litter, and placing the mixture in a sealed bag before disposal in household trash. Identifying information should be scratched out from the packaging, and the product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Irenka found in:

A-Z Index: